How to buy Biogen stock

Biogen Inc is a drug manufacturers—general business based in the US. Biogen shares (BIIB) are listed on the NASDAQ and all prices are listed in US Dollars. Biogen employs 7,400 staff and has a trailing 12-month revenue of around USD$14.5 billion.

How to buy shares in Biogen

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Biogen Find the stock by name or ticker symbol: BIIB. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Biogen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Biogen, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Biogen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Biogen share price

Use our graph to track the performance of BIIB stocks over time.

Biogen shares at a glance

• Key figures

Information last updated 2020-09-25.

52-week range	USD$219.7 - USD$374.99
50-day moving average	USD$280.0606
200-day moving average	USD$290.3916
Wall St. target price	USD$305.14
PE ratio	7.9965
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$34.044

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Biogen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Biogen Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Biogen under- or over-valued?

Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biogen's P/E ratio

Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Biogen shares trade at around 8x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Biogen's PEG ratio

Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Biogen's EBITDA

Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$8 billion.

The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.

Biogen financials

Revenue TTM	USD$14.5 billion
Operating margin TTM	52.37%
Gross profit TTM	USD$12.4 billion
Return on assets TTM	18.31%
Return on equity TTM	49.38%
Profit margin	40.91%
Book value	$71.438
Market capitalisation	USD$42.5 billion

TTM: trailing 12 months

Shorting Biogen shares

There are currently 3.3 million Biogen shares held short by investors – that's known as Biogen's "short interest". This figure is 39.1% up from 2.4 million last month.

There are a few different ways that this level of interest in shorting Biogen shares can be evaluated.

Biogen's "short interest ratio" (SIR)

Biogen's "short interest ratio" (SIR) is the quantity of Biogen shares currently shorted divided by the average quantity of Biogen shares traded daily (recently around 1.3 million). Biogen's SIR currently stands at 2.63. In other words for every 100,000 Biogen shares traded daily on the market, roughly 2630 shares are currently held short.

However Biogen's short interest can also be evaluated against the total number of Biogen shares, or, against the total number of tradable Biogen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biogen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Biogen shares in existence, roughly 20 shares are currently held short) or 0.021% of the tradable shares (for every 100,000 tradable Biogen shares, roughly 21 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biogen.

Find out more about how you can short Biogen stock.

Biogen's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biogen.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Biogen's total ESG risk score

Total ESG risk: 23.93

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biogen's overall score of 23.93 (as at 08/01/2020) is pretty good – landing it in it in the 33rd percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Biogen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Biogen's environmental score

Environmental score: 1.02/100

Biogen's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Biogen's social score

Social score: 13.48/100

Biogen's social score of 13.48 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Biogen's governance score

Governance score: 8.43/100

Biogen's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Biogen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Biogen's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Biogen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Biogen has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Biogen Inc was last rated for ESG on: 2020-08-01.

Total ESG score	23.93
Total ESG percentile	33.4
Environmental score	1.02
Environmental score percentile	2
Social score	13.48
Social score percentile	2
Governance score	8.43
Governance score percentile	2
Level of controversy	2

Biogen share dividends

We're not expecting Biogen to pay a dividend over the next 12 months.

Have Biogen's shares ever split?

Biogen's shares were split on a 3:1 basis on 18 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.

Biogen share price volatility

Over the last 12 months, Biogen's shares have ranged in value from as little as $219.7 up to $374.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is 0.5234. This would suggest that Biogen's shares are less volatile than average (for this exchange).

Biogen overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Biogen is owned by insiders or institutions?

  Currently 0.657% of Biogen shares are held by insiders and 93.155% by institutions.

• How many people work for Biogen?

  Latest data suggests 7,400 work at Biogen.

• When does the fiscal year end for Biogen?

  Biogen's fiscal year ends in December.

• Where is Biogen based?

  Biogen's address is: 225 Binney Street, Cambridge, MA, United States, 02142

• What is Biogen's ISIN number?

  Biogen's international securities identification number is: US09062X1037

• What is Biogen's CUSIP number?

  Biogen's Committee on Uniform Securities Identification Procedures number is: 09062X103